Market Size of Biomarkers Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 51.5 Billion |
Market Size (2029) | USD 87.60 Billion |
CAGR (2024 - 2029) | 11.21 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Biomarkers Market Analysis
The Biomarkers Market size is estimated at USD 51.5 billion in 2024, and is expected to reach USD 87.60 billion by 2029, growing at a CAGR of 11.21% during the forecast period (2024-2029).
Factors such as the high prevalence of cancer and cardiac problems and biomarker advancements can be attributed to the growth of the biomarkers market. The spike in cancer cases globally has increased the use of advanced technology such as biomarkers. For instance, according to an article published by the Chinese Medical Journal in March 2022, approximately 4.8 million new cancer cases were registered in China in 2022, out of which the most common was lung cancer. Such an increase in the burden of cancer will likely push companies to develop newer targets for cancer diagnosis, ultimately boosting the demand for biomarkers over the coming years.
According to an article published by PubMed Central in April 2022, new electroencephalogram (EEG) based non-invasive techniques with bodily fluid biomarkers are being developed, which may offer a more accurate prediction of Alzheimer’s disease status in the patient. The article also stated that several minimally invasive techniques are being developed, and several biomarkers are being found to predict Alzheimer’s disease from blood, saliva, and urine. Thus, with the increasing prevalence of life-threatening diseases and the rising usage of biomarkers in diagnosing and treating those diseases, the demand for biomarkers in accurately diagnosing the condition is anticipated to grow, boosting the market's growth.
The launch of biomarker tests by market players is also augmenting the market's growth. For instance, in July 2022, Labcorp launched one of the first widely accessible tests that provide direct evidence of neurodegeneration and neuronal injury. The Neurofilament Light Chain (NfL) is a blood biomarker test that allows doctors to identify and verify signs of neurodegenerative disease, providing a more effective and efficient path to diagnosis and treatment for patients. Elevated NfL levels signal neuronal injury, whether from diseases like multiple sclerosis, Alzheimer’s, and Parkinson’s, or brain injury, such as concussion.
Thus, owing to the above-mentioned factors, such as the rising prevalence of life-threatening diseases, the rising usage of biomarkers in disease diagnosis, and increasing product launches, the market is expected to grow over the forecast period. However, issues related to regulatory and reimbursement systems and the high cost of biomarkers may hinder the market's growth.
Biomarkers Industry Segmentation
As per the scope of the report, a biomarker refers to a biomolecule or gene used to precisely evaluate the body's pharmacologic, pathogenic, and biological procedures. They serve as an early warning system in the body. It can also be stated as a traceable subsite introduced into the body to check or examine the organ's function. It can be measured and evaluated by using blood, urine, or soft tissues.
The biomarkers market is segmented by disease, type, mechanism, and geography. By disease, the market is segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, renal disorders, and other diseases. By type, the market is segmented into efficacy biomarkers, safety biomarkers, and validation biomarkers. By mechanism, the market is segmented into genetic, epigenetic, proteomic, lipidomic, and other mechanisms. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD) for all the above-mentioned segments.
By Disease | |
Cancer | |
Cardiovascular Disorders | |
Neurological Disorders | |
Immunological Disorders | |
Renal Disorders | |
Other Diseases |
By Type | ||||||
| ||||||
Safety Biomarkers | ||||||
Validation Biomarkers |
By Mechanism | |
Genetic Biomarkers | |
Epigenetic Biomarkers | |
Proteomic Biomarkers | |
Lipidomic Biomarkers | |
Other Mechanisms |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Biomarkers Market Size Summary
The biomarkers market is poised for significant growth, driven by the increasing prevalence of cancer and cardiac conditions, alongside advancements in biomarker technology. The rising incidence of cancer globally has necessitated the adoption of advanced diagnostic tools, including biomarkers, to enhance cancer detection and treatment. Similarly, the development of non-invasive techniques for predicting Alzheimer's disease using bodily fluid biomarkers underscores the expanding role of biomarkers in diagnosing and managing life-threatening diseases. The introduction of innovative biomarker tests by key market players further propels market expansion, despite challenges related to regulatory and reimbursement frameworks and the high costs associated with biomarker applications.
Epigenetic biomarkers are gaining traction due to their ability to detect and quantify epigenetic changes through minimally invasive procedures, offering promising applications in disease identification, staging, and clinical management. The growing prevalence of lifestyle-related diseases and cancer, coupled with strategic initiatives by market players, is expected to drive the segment's growth. North America is anticipated to hold a substantial share of the biomarkers market, supported by the increasing approval of molecular biomarker-based drug labels and a high burden of neurological conditions. The market's competitive landscape is characterized by significant investments in research and development, with major pharmaceutical companies and governments focusing on technological advancements to foster market growth.
Biomarkers Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Prevalence of Life Threatening Diseases
-
1.2.2 Increasing Demand for Early Diagnosis of Diseases
-
1.2.3 Research Advancements in Finding New Biomarkers
-
-
1.3 Market Restraints
-
1.3.1 Issues Related to Regulatory and Reimbursement Systems
-
1.3.2 High Cost of Biomarkers
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value – USD)
-
2.1 By Disease
-
2.1.1 Cancer
-
2.1.2 Cardiovascular Disorders
-
2.1.3 Neurological Disorders
-
2.1.4 Immunological Disorders
-
2.1.5 Renal Disorders
-
2.1.6 Other Diseases
-
-
2.2 By Type
-
2.2.1 Efficacy Biomarkers
-
2.2.1.1 Prognostic Biomarkers
-
2.2.1.2 Pharmacodynamic Biomarkers
-
2.2.1.3 Surrogate End Point Markers
-
2.2.1.4 Predictive Biomarkers
-
-
2.2.2 Safety Biomarkers
-
2.2.3 Validation Biomarkers
-
-
2.3 By Mechanism
-
2.3.1 Genetic Biomarkers
-
2.3.2 Epigenetic Biomarkers
-
2.3.3 Proteomic Biomarkers
-
2.3.4 Lipidomic Biomarkers
-
2.3.5 Other Mechanisms
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Biomarkers Market Size FAQs
How big is the Biomarkers Market?
The Biomarkers Market size is expected to reach USD 51.5 billion in 2024 and grow at a CAGR of 11.21% to reach USD 87.60 billion by 2029.
What is the current Biomarkers Market size?
In 2024, the Biomarkers Market size is expected to reach USD 51.5 billion.